Want to see IN:SUVEN full AI Analyst Report?
SUVEN Stock Chart & Stats
₹165.00
₹14.56(11.52%)
At close: 4:00 PM EST
₹165.00
₹14.56(11.52%)
Day’s Range― - ―
52-Week Range₹124.35 - ₹371.00
Previous CloseN/A
Volume2.87M
Average Volume (3M)14.83K
Market Cap
₹81.07B
Enterprise Value₹30.02K
Total Cash (Recent Filing)₹5.18B
Total Debt (Recent Filing)₹166.94M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.41
Shares Outstanding263,992,550
10 Day Avg. Volume16,308
30 Day Avg. Volume14,834
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)5.07
Price to Sales (P/S)421.72
P/FCF Ratio-9.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Limited DebtMinimal debt reduces solvency risk and gives management room to pursue R&D or licensing without urgent refinancing needs. Over a 2–6 month horizon, low leverage preserves optionality for strategic partnerships or milestone financing while limiting interest burdens on a cash-burning operation.
Recent Top-line ImprovementA substantial FY2026 revenue uptick signals regained commercial traction or successful project milestones. If sustained, stronger top-line momentum supports longer-term R&D investment and potential scale benefits, making future margin recovery and partner interest more attainable.
R&D / IP-driven Business ModelSpecialization in CNS drug discovery and an IP-generation model are durable strategic assets: they create high barriers to entry, support licensing or collaboration revenue streams, and can yield long-term value from successful candidates even while near-term earnings remain negative.
Bears Say
Persistent Operating And Net LossesRecurring operating and net losses indicate the core business is not yet profitable. Over months this undermines self-funding ability, increases dependence on external capital, and raises the bar for sustaining R&D spend or commercial expansion without dilutive financing or partnerships.
Negative Cash Generation / Accelerating Cash BurnConsistent negative operating and free cash flows mean the company cannot fund operations from internal cash; accelerated FY2026 burn shortens runway. This structural cash gap forces external financing or asset monetization, which can dilute shareholders or delay programs.
Poor Returns And Capital ProductivityNegative and volatile returns on equity signal that invested capital has not generated value historically. Over a multi-month horizon this weakens investor confidence in scaling the business internally and complicates negotiations for non-dilutive partnerships or attractive funding terms.
Suven Life Sciences Limited News
SUVEN FAQ
What was Suven Life Sciences Limited’s price range in the past 12 months?
Suven Life Sciences Limited lowest stock price was ₹124.35 and its highest was ₹371.00 in the past 12 months.
What is Suven Life Sciences Limited’s market cap?
Suven Life Sciences Limited’s market cap is ₹81.07B.
When is Suven Life Sciences Limited’s upcoming earnings report date?
Suven Life Sciences Limited’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Suven Life Sciences Limited’s earnings last quarter?
Suven Life Sciences Limited released its earnings results on May 13, 2026. The company reported -₹1.729 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Suven Life Sciences Limited overvalued?
According to Wall Street analysts Suven Life Sciences Limited’s price is currently Overvalued.
Does Suven Life Sciences Limited pay dividends?
Suven Life Sciences Limited pays a Annually dividend of ₹1.382 which represents an annual dividend yield of N/A. See more information on Suven Life Sciences Limited dividends here
What is Suven Life Sciences Limited’s EPS estimate?
Suven Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suven Life Sciences Limited have?
Suven Life Sciences Limited has 263,992,550 shares outstanding.
What happened to Suven Life Sciences Limited’s price movement after its last earnings report?
Suven Life Sciences Limited reported an EPS of -₹1.729 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.532%.
Which hedge fund is a major shareholder of Suven Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:SUVEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suven Life Sciences Limited
Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative conditions across key markets including India, the United States, Europe, and other international territories. The company's core activities revolve around the discovery and subsequent development of new chemical entities (NCEs) specifically targeting disorders of the central nervous system (CNS). Among its promising pipeline assets are SUVN-502, intended for Alzheimer's disease and associated neuropsychiatric manifestations; SUVN-G3031, a potent and selective inverse agonist of the histamine H3 receptor, aimed at sleep and cognitive impairments; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist designed to alleviate depressive disorders. Further advancing its portfolio, Suven is also working on SUVN-D4010, a potent, selective, orally bioavailable, and brain-penetrant partial agonist of the 5-HT4 receptor for cognitive dysfunctions; SUVN-I6107, addressing cognitive issues and schizophrenia; SUVN-M8036 for various psychiatric ailments; and SUVN-D1044, targeting gastrointestinal conditions. Established in 1989, the company is based in Hyderabad, India. It adopted its current name, Suven Life Sciences Limited, in 2003, having previously operated as Suven Pharmaceuticals Pvt. Ltd. Jasti Property and Equity Holdings Private Limited holds a controlling interest in Suven Life Sciences Limited, making it a subsidiary.
Technical Analysis
Divi's Laboratories Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Sun Pharma Advanced Research Co. Ltd.
―